Could a bladder pill cool down breast cancer hot flashes?

NCT ID NCT01530373

Recruiting now Symptom relief Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two drugs—solifenacin (used for overactive bladder) and clonidine (a common hot flash treatment)—to see which better reduces hot flashes in breast cancer patients on hormone therapy. About 110 women will take one of the pills daily for three weeks and track their symptoms. The goal is to find a more effective way to ease this common side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: solifenacin (Vesicare) and clonidine (Catapres, Dixarit)
What this could lead to: If solifenacin works better than clonidine, it could offer a new option for managing hot flashes in breast cancer survivors.
What could go wrong: This is a small, early-phase study with only 110 participants. The drug may not prove more effective than clonidine, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Hot Flashes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HOT FLASHES

Contacts and locations

Locations

Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
RECRUITING

Little Rock, Arkansas, 722205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.